Vigorous IV Hydration Regimen Cuts Post-ERCP Pancreatitis Risk

Share this content:
Vigorous IV Hydration Regimen Cuts Post-ERCP Pancreatitis Risk
Vigorous IV Hydration Regimen Cuts Post-ERCP Pancreatitis Risk

THURSDAY, Dec. 22, 2016 (HealthDay News) -- Vigorous periprocedural intravenous fluid resuscitation (IVFR) with lactated Ringer's solution can reduce the incidence and severity of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in average-risk and high-risk cases, according to a study published in the January issue of Clinical Gastroenterology and Hepatology.

Jun-Ho Choi, M.D., from Dankook University College of Medicine in Cheonan, Korea, and colleagues randomly assigned 510 patients (1:1) to either vigorous IVFR (lactated Ringer's solution in an initial bolus of 10 mL/kg before the procedure, 3 mL/kg/h during the procedure and for eight hours after the procedure, and a post-procedure bolus of 10 mL/kg) or a standard IVFR (lactated Ringer's solution at 1.5 mL/kg/h during and for eight hours after the procedure).

The researchers found that the main indications for ERCP were choledocholithiasis (58 percent) and malignant biliary stricture (27 percent). Post-ERCP pancreatitis developed in 11 patients in the vigorous IVFR group and 25 patients in the standard IVFR group (relative risk, 0.41; P = 0.016). In the vigorous group, a significantly smaller proportion of patients developed moderate or severe acute pancreatitis versus the standard IVFR group (P = 0.040). One patient in the vigorous IVFR group developed peripheral edema.

"Additional confirmatory studies will be necessary to support our conclusions and to assess the optimal protocol and volume of IVFR," the authors write.

Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »